Odunsi K - Search Results

1

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.

Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. Zsiros E, et al. Among authors: odunsi k. JAMA Oncol. 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. JAMA Oncol. 2021. PMID: 33211063 Free PMC article. Clinical Trial.

2

Human ovarian cancer, lymphoma spleen, and bovine milk GlcNAc:beta1,4Gal/GalNAc transferases: two molecular species in ovarian tumor and induction of GalNAcbeta1,4Glc synthesis by alpha-lactalbumin.

Chandrasekaran EV, Chawda R, Piskorz C, Locke RD, Ta A, Sharad G, Odunsi K, Lele S, Matta KL. Chandrasekaran EV, et al. Among authors: odunsi k. Carbohydr Res. 2001 Aug 23;334(2):105-18. doi: 10.1016/s0008-6215(01)00150-1. Carbohydr Res. 2001. PMID: 11502266

3

The impact of pre-therapy extraperitoneal surgical staging on the evaluation and treatment of patients with locally advanced cervical cancer.

Odunsi KO, Lele S, Ghamande S, Seago P, Driscoll DL. Odunsi KO, et al. Eur J Gynaecol Oncol. 2001;22(5):325-30. Eur J Gynaecol Oncol. 2001. PMID: 11766731

4

Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases.

Anupol N, Ghamande S, Odunsi K, Driscoll D, Lele S. Anupol N, et al. Among authors: odunsi k. Gynecol Oncol. 2002 Jun;85(3):487-92. doi: 10.1006/gyno.2002.6653. Gynecol Oncol. 2002. PMID: 12051879

5

Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.

Odunsi K, Ghamande S, Chandrasekaran EV, Ta A, Moysich KB, Driscoll D, Matta K, Lele S. Odunsi K, et al. Am J Obstet Gynecol. 2002 Sep;187(3):575-80. doi: 10.1067/mob.2002.125888. Am J Obstet Gynecol. 2002. PMID: 12237630

6

Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer.

Ghamande S, Lele S, Marchetti D, Baker T, Odunsi K. Ghamande S, et al. Among authors: odunsi k. Int J Gynecol Cancer. 2003 Mar-Apr;13(2):142-7. doi: 10.1046/j.1525-1438.2003.13045.x. Int J Gynecol Cancer. 2003. PMID: 12657114 Clinical Trial.

7

NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.

Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ. Odunsi K, et al. Cancer Res. 2003 Sep 15;63(18):6076-83. Cancer Res. 2003. PMID: 14522938

8

Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules.

Ghadersohi A, Odunsi K, Lele S, Collins Y, Greco WR, Winston J, Liang P, Sood AK. Ghadersohi A, et al. Among authors: odunsi k. Oncol Rep. 2004 Feb;11(2):453-8. Oncol Rep. 2004. PMID: 14719083

9

Primary primitive neuroectodermal tumor of the uterus: a report of two cases and review of the literature.

Odunsi K, Olatinwo M, Collins Y, Withiam-Leitch M, Lele S, Spiegel GW. Odunsi K, et al. Gynecol Oncol. 2004 Feb;92(2):689-96. doi: 10.1016/j.ygyno.2003.09.029. Gynecol Oncol. 2004. PMID: 14766268 Review.

10

Clinicopathologic outcomes of laser conization for high-grade cervical dysplasia.

dos Santos L, Odunsi K, Lele S. dos Santos L, et al. Among authors: odunsi k. Eur J Gynaecol Oncol. 2004;25(3):305-7. Eur J Gynaecol Oncol. 2004. PMID: 15171305

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

383 results

Search Page